Protection against the Extravasation of Anticancer Drugs by Standardization of the Management System
Hiroyuki Watanabe(Tokyo Medical and Dental University), Ryozo Oishi(Kyushu University Hospital), Masanori Sueyasu(Kyushu University), Hiroaki Ikesue(Kobe City Medical Center General Hospital), Minoru Yoshida(Chemotherapy Foundation), Yoichi Nakanishi(RIKEN Center for Integrative Medical Sciences), Tomoichiro Koga, Ichiro Inoshima, Naoko Yamamoto(Disco (japan)), Nobuaki Egashira(Wakayama Medical University), Setsuko Sakamoto(Kyushu University Hospital)
Cited by 14
Related Papers
Loss of Suppressor of Cytokine Signaling 1 in Helper T Cells Leads to Defective Th17 Differentiation by Enhancing Antagonistic Effects of IFN-γ on STAT3 and Smads
|The Journal of Immunology|2008|183
Randomized Phase III Study Comparing Gefitinib With Erlotinib in Patients With Previously Treated Advanced Lung Adenocarcinoma: WJOG 5108L
|Journal of Clinical Oncology|2016|160
Pretaporter, a Drosophila protein serving as a ligand for Draper in the phagocytosis of apoptotic cells
|The EMBO Journal|2009|99
Genomic Structure and Transcriptional Regulation of the Rat, Mouse, and Human Carboxylesterase Genes
|Drug Metabolism Reviews|2007|90